Podcast

Dr. Lutz discusses testicular cancer awareness

Author(s):

Urology Times staff

“While we have these young men in our offices, we need to try and engage them for all of the necessary screening opportunities that will improve the quality of their lives moving forward,” says Michael Lutz, MD, in this podcast episode.

In this episode, Urology Times® Assistant Managing Editor Ben Saylor spoke with Dr. Michael Lutz about how urologists can raise testicular cancer awareness among their patients. Lutz is a partner in the Michigan Institute of Urology and is president of the MIU Men’s Health Foundation.

Related Videos
A panel of 5 experts on bladder cancer
A panel of 5 experts on bladder cancer
A panel of 5 experts on bladder cancer
A panel of 5 experts on bladder cancer
A panel of 5 experts on bladder cancer
A panel of 5 experts on bladder cancer
A panel of 5 experts on bladder cancer
A panel of 5 experts on bladder cancer
A panel of 5 experts on bladder cancer
Related Content
The potential role for IsoPSA in prostate cancer risk assessment
June 23rd 2024

The potential role for IsoPSA in prostate cancer risk assessment

Urology Times staff
"Looking at data, if you apply IsoPSA in a consistent manner, based on the studies published, you'll see up to a 55% reduction in unnecessary biopsies," says Jason M. Hafron, MD.
Former MLB player Dave Winfield shares lessons from baseball, philanthropy
November 15th 2024

Former MLB player Dave Winfield shares lessons from baseball, philanthropy

Urology Times staff
In this episode of Speaking of Urology, former MLB player Dave Winfield shares lessons he’s learned throughout his professional baseball career and his work in philanthropy.
Michigan Institute of Urology opens dedicated outpatient medical center for minimally invasive health care
December 13th 2023

Michigan Institute of Urology opens dedicated outpatient medical center for minimally invasive health care

Michigan Institute of Urology
The center will offer a comprehensive range of treatments, including prostate artery embolization for men suffering from benign prostatic hyperplasia with very large prostates.
Key updates from the AUA/ASRM male infertility guideline amendment
September 23rd 2024

Key updates from the AUA/ASRM male infertility guideline amendment

Urology Times staff
In this episode, Robert E. Brannigan, MD, and Juan J. Andino, MD, MBA, discuss the recent amendment to the AUA/ASRM guideline on male infertility.
Conceptual image for prostate cancer treatment | Image Credit: © Dr_Microbe - stock.adobe.com
September 18th 2023

PSMA uptake, access appear high for US-based urologists

Benjamin P. Saylor
An exclusive Urology Times survey measured US-based urologists’ uptake, access to, and indications for utilizing prostate-specific membrane antigen-targeting agents.
blur image background of corridor in hospital or clinic image | Image Credit: © whyframeshot - stock.adobe.com
August 30th 2023

ECLIPSE trial evaluating PSMA agent for metastatic castration-resistant prostate cancer

Urology Times staff
"The purpose of the study is to compare the safety and efficacy of lutetium PSMA I&T vs standard of care hormone therapy in patients with metastatic castration-resistant prostate cancer," says Jason M. Hafron, MD.
© 2024 MJH Life Sciences

All rights reserved.